Catalyst Pharmaceuticals’ (CPRX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) in a research report sent to investors on Friday morning,Benzinga reports. The brokerage currently has a $30.00 target price on the biopharmaceutical company’s stock. Several other brokerages have also recently issued reports on CPRX. Citigroup raised their price objective on […]

Leave a Reply

Your email address will not be published.

Previous post Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Hits New 52-Week Low – Time to Sell?
Next post Scotiabank Cuts Akamai Technologies (NASDAQ:AKAM) Price Target to $112.00